Cassava Sciences Inc
SAVA.O- Latest Trade
- trading lower24.31USD
- -0.17
- 0.69%
- As of Jun 10 2023. Values delayed up to 15 minutes
- Today's Range
- 23.79 - 24.63
- 52 Week Range
- 13.84 - 51.59
- Previous Close
- 24.48
- Open
- 24.63
- Volume
- 610,491.00
- 3 Month Average Trading Volume
- 14.40
- Shares Out (Mil)
- 41.75
- Market Cap
- 1,014.93
- Forward P/E
- -30.97
- Dividend Yield
- 0.00
Key Statistics
2.00 mean rating - 2 analysts
- P/E Excl. Extra Items (TTM)
- 0.00
- Price To Sales (TTM)
- 0.00
- Price To Book (Quarterly)
- 4.98
- Price To Cash Flow (Per Share TTM)
- 0.00
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -37.59
- Return On Equity (TTM)
- -35.90
2021 (millions USD)
About Cassava Sciences Inc (SAVA.O)
Company Information
Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in the detection and treatment of neurodegenerative diseases, such as Alzheimer’s disease. The Company develops pharmaceutical product candidates that offer improvements to patients and healthcare professionals. The Company has two biopharmaceutical assets under development, including its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer’s disease dementia, which is under Phase III clinical studies; and its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. Simufilam is a proprietary small molecule (oral) drug, which targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. SavaDx is designed as an antibody-based detection system for altered filamin A (FLNA).
Address
6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300AUSTIN, TX
78731
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Remi Barbier
- Chairman of the Board, President, Chief Executive Officer
- Eric J. Schoen
- Chief Financial Officer
- R. Christopher Cook
- Senior Vice President, General Counsel
- James W. Kupiec
- Chief Medical Officer
- Sanford R. Robertson
- Lead Independent Director
- Richard J. Barry
- Independent Director
- Robert Z. Gussin
- Independent Director
- Michael J. O'Donnell
- Independent Director
- Patrick J. Scannon
- Independent Director
Latest News
- MarketsZillow Group, Under Armour, Newell Brands, AMD
U.S. stock indexes were mixed in choppy trading on Friday as investors digested hot inflation data that spurred a sharp selloff in the previous session on fears about aggressive interest rate hikes by the Federal Reserve.
- MarketsZillow Group, GoDaddy, Surgalign Holdings
U.S. stock futures pointed to a fresh round of selling on Friday, sparked by growing expectations for quicker interest rate hikes from the Federal Reserve following data that showed soaring inflation.
- MarketsBlackBerry, Boeing, Mastercard, Banks, COVID-19 vaccine stocks
Wall Street's main indexes rose more than 1% on Tuesday, boosted by Nike and Micron following strong earnings, while beaten-down big technology stocks bounced back from an Omicron-driven rout in the previous session.
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,960.30 | 0.17% |
| Copper | 723.65 | 0.19% |
| Brent Crude Oil | 74.79 | -- |
| CBOT Soybeans | 1,387.75 | 1.80% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,298.86 | 0.11% |
| Euro STOXX 50 | 4,289.79 | 0.18% |
| FTSE 100 | 7,562.36 | 0.49% |
| Nikkei 225 | 32,265.17 | 1.97% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes